Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management.
Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality.
By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment.
As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens.
Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes.
However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments.
In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
Healthcarestocks
Long-term bottoms for Position Trade OpportunitiesNASDAQ:TWST reports tomorrow and has been trending up but doesn't have a pre earnings run. However, the stock has completed a long term bottom which provides strong support. Position trade candidate after the earnings volatility settles out. Institutional Holdings are very high.
Centene Corp | CNC | Long at $65As a managed health care company, Centene Corp NYSE:CNC doesn't get much attention. However, it is an undervalued growth stock. It's been a workhorse historically for slow and steady financial returns with a 3%+ dividend. The biggest dips along my selected moving average have been into the blue lines - which it recently tested. While the stock may close the gap near $62 is the near future, it's a personal buy at $65.
Target 1 = $78.00
Target 2 = $95.00
Swing Trading Setups: TWSTThis is a stock that went on my students' watchlists this week for potential swing trading.
NASDAQ:TWST is coming out of a long-term down-trending correction and has completed the bottom. Accumulation ended and a HFT gap and run up followed on May 3rd. The stock retested the sideways trend highs which are now support for the current price.
Pro traders are swing trading in these patterns. There are fewer wicks and tails and the stock has a very high Percentage of Shares Held by Institutions.
HIMS a gender focused health care company LONGHIMS had an excellent earnings report for a small cap company; it is consumer driven quality
focused and helps the customer feel good about him/her- self. It does not have any gender
orientation agenda nor any obvious political inclinations. On the 120 minute chart, it started
a moving averge convergence about a week before earnings. The Greeny TTM squeeze indicator
did its thing as the post-earnings action began. I see this stock as a good long to hold into
the next earnings and perhaps through it. HIMS is now at its all time high. There is no chart
horizontal resistance overhead and traders will note that. I see the bullish momentum
continuing perhaps with some healthy ( no pun intended) corrections while underway.
Healthcare is considered to be a hot sector for 2024 this small cap seems to be warmed up.
UNITED HEALTH Time to buy again?Last time we looked into United Health (UNH) we gave a strong buy signal (October 03 2023, see chart below), which turned out to be very successful:
After getting rejected on Resistance 3, the stock started to decline structurally within a Channel Down. It is a pattern similar to the Channel Down of November 2022 - March 2023, which was again formed after UNH got rejected within the 2-year Resistance Zone, like it happened this time.
There is a high symmetry these past 2 years within the Resistance and Support Zones, so we expect the price to act accordingly. As a result, having already formed a 1D Death Cross, we expect the price to make one last Low towards the Support Zone (as long as the 1D MA50 holds as Resistance) and then rebound, which is what took place on March 10 2023, above the 0.618 Fibonacci retracement level.
As a result, we will time our buy accordingly and target $517.00 (Fib 0.618). An additional buy signal would be if the 1W RSI makes a Double Bottom, similar again to March 10 2023.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
ELI LILLY Going to $1050 but after a 1D MA50 correction.Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity.
The 1D RSI in particular has a Buy Zone, which coincided with all those dip buy opportunities within the Channel Up. As a result, since the stock has already completed a +45% rise from the October 31 2023 Low, we do expect a pull-back to start soon towards the RSI Buy Zone, but only after it rises a little again and forms a Lower High on the RSI, which would be consistent with the previous top formation on the Channel Up.
In any case, at any point the RSI hits its Buy Zone, we will position ourselves with a long and aim for a new +45% rise. Rough target from the current projection is $1050. Notice how efficiently the peak and bottom formations are caught by the Sine Waves. A very symmetric pattern for the long-term indeed.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
Dr Lal Pathlabs Ltd can it double in one year?Dr Lal Pathlabs one of the largest players of healthcare industry in India has a beaten down stock price currently. It is approximately 53.29% down from it's lifetime high. There is not a single reason for such stock price. The company is posting good results and is consistently showing profits. But the stock is highly undervalued. It is a good time to buy it as the current levels make it a precious deal to make.
Hope you like my analysis.
Please do your own study before investing.
Do like and follow and share among your family and friends.
Thank you.
UNH, the dominate health insurance market leader LONGAs shown on the 4H chart, UNH based on a long-term VWAP band setup, it as fiar value for the
first time since September. This dip is significant as price fell from a head and shoulders pattern
of three months duration. The candles in the past couple of days show the reversal at the
mean VWAP support. I have retrieved 60% out of a near term expiration call option. Some may
say this is simply a death cross on a pair of moving averages with a bit of correction on the
overall downtrend. I understand that point of view. Notwithstanding that perspective,
healthcare is expected to be an outperforming sector in 2024. UNH is on sale. As a healthcare
provider, it has paid me large sums in the historical past. I will take trades as described
in the text box on the chart. I believe buying out of the money and at a discount will be
a good strategy for this megacap moving forward.
CANO a healthcare penny stock with high volatility LONGCANO is shown on a 15-minute chart now set for a long position with comments on the chart.
This is a VWAP band breakout with a volatility spike long trade.
Stop loss is about 70 cents, targets are 70 cents, $1.40 and $2.10 for 33% each and a reward
of $2 for every $1 risked. Options are available for one and two months expiration.
The Healthcare Sector Index $XLV - Worth Watching SPDR Select Sector Fund – Healthcare Index AMEX:XLV
The chart speaks for itself, we have our breakout levels and our break down levels. We enter on a breakout and set a stop 5% under that support and we exit and or short if we fall under the two underside support levels.
Below I outline some reasons why the healthcare sector is worth paying attention too.
The healthcare industry is worth $808 billion in the United States as of 2021. 65% of the industry’s revenue comes from patient care. The global healthcare industry is worth $12 trillion.
In the U.S National health expenditures are projected to grow 5.4 percent, on average, over the course of 2023–31 and to account for roughly 20 percent of the economy by the end of that period. The insured share of the population is anticipated to exceed 92 percent through 2023 (figures pending), in part as a result of record-high Medicaid enrolment, and then decline toward 90 percent as coverage requirements related to the COVID-19 public health emergency expire.
The growth of the health-care sector is evident in employment data as well. In 1990, about 8 million Americans worked in health care; that figure has since doubled to 16 million. That’s the largest single employment segment in our economy.
In addition to the above, the west in general is an aging populace that is living longer. We will need these services more than we need staples during a recession. I believe this index can help us gauge the healthcare sector and what direction it will go next. We can watch the levels outlines and make a play if we wish. We have a hard upper boundary and lower boundary on a parallel channel on the chart. You know what to do when we breach any of these levels.
Outlined on the chart
XLV fund provides exposure to companies in
pharmaceuticals, health care equipment and supplies,
health care providers and services, biotechnology, life
sciences tools and services, and health care
technology industries. XLV is the oldest in the
segment, as such it is used widely for strategic or
tactical positions. Since XLV is both cap weighted
and fishes only from the S&P 500, it tilts heavily
toward mega-caps. For focused exposure to
leading health care names, XLV is tough to beat.
Top Five Holdings
UnitedHealth Group Inc NYSE:UNH 9.63%
Eli Lilly and Co NYSE:LLY 9.19%
Johnson & Johnson NYSE:JNJ 7.46%
Merck & Co NYSE:MRK 5.46%
AbbVie Inc 5.41%
Stay Healthy and Nimble Folks
PUKA
Analysis of CVS Stock Trends: A Parabolic Turn on the HorizonFashionable Analysis of CVS Stock Trends: A Parabolic Turn on the Horizon
Introduction:
In the realm of financial fashion, CVS stock is set to make a stylish entrance with a parabolic turn, showcasing a strong formation on the 4D timeframe. This trend is marked by the elegant falling wedge pattern and the chic double bottom overlapping patterns, following a dose of impactful news related to drug patents.
Technical Analysis - CVS Stock:
The 4D timeframe reveals the graceful formation of a falling wedge pattern, signifying a poised parabolic turn in CVS stock. This pattern, complemented by double bottom overlapping formations, is a testament to the stock's resilience, especially against the backdrop of recent drug patent news highlighted on CNBC ( www.cnbc.com ).
Price Targets and Corrections:
The first take profit target stands confidently at $76.78, offering investors a lucrative moment to capitalize on the impending parabolic turn. Following this peak, a correction to approximately $71.07 is expected, providing a brief pause for market adjustments.
Strategic Entry and Second Take Profit Target:
Wise investors can strategically enter the market around $71.07, anticipating a second take profit target at a stylish $82.44. This forecasted move aligns with the rhythm of the stock's recent patterns, emphasizing the importance of timing in the world of financial fashion.
Historical Elegance:
Tracing CVS stock's journey since April 2019, a period marking the middle of the pandemic, unveils a remarkable rally. The stock gracefully formed a strong falling wedge pattern on the 4Day timeframe, echoing a sense of resilience and adaptability. The rally continued, reaching its peak around February 01, 2022, before gracefully correcting until October 25, 2023.
Future Projections:
As the music of the market plays on, further continuation of this trend is expected. The forecasted trajectory anticipates a new level of elegance for CVS stock by the end of 2024, reaching a poised $106.97. This future projection exudes confidence and sets the stage for CVS to make a bold statement in the financial fashion world.
In the intricate dance of stocks and patterns, CVS is poised to captivate investors with its upcoming parabolic turn and a tale of resilience, gracefully crafted on the canvas of market trends.
Is Sanofi Undervalue by 22% ?I wanted to share an analysis I've conducted on Sanofi over the past five years using both comparable methods and a 2-Stage DCF approach. According to my findings, the market value appears to be at least 22% undervalued in comparison with its fair value. Moreover, considering the post-COVID effects on pharmaceutical companies, I believe Sanofi presents a compelling opportunity to purchase its stock with potentially lower risk.
I would be glad to share my detailed analysis for any one interested in more in debt explorations
Disclaimer:
This information is based on my personal analysis and is not to be considered financial advice. I am expressing my own views and opinions on the current market conditions and Sanofi's stock. Always conduct your own research and consider seeking advice from a qualified financial professional before making any investment decisions.
Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️
I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise.
This is how you build real long term wealth!
In today's anaylsis I want to take a look at the bigger picture on Pfizer.
At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past.
Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside.
- - - - - - - - - - - - - - - - - - - -
I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy.
Keep the long term vision🫡
Current Developments on CVS chart can make for opportunityHi guys! This is a Technical analysis on CVS Health Corporation (CVS) on the 3 day timeframe.
We discuss some Current developments on CVS, which maybe pointing to signs of potential opportunity to invest/ hold CVS.
We've had a deathcross that has brought us down more than 38%.
Which has lead us to a critical support trendline that has acted as support since March 2019.
We recently bounced from this trendline with a BULLISH ENGULFING candle print
We have from this support line bounced up to reach the 21 EMA
Current price action is attempting to establish support on 21 EMA.
MACD has crossed Bullish with Green bars printing.
BUT also remember that we have resistance above us from the 50 SMA.
We are also in an established DOWNTREND from the Deathcross. Until proven otherwise so we have to pay attention for signs of trend change.
Key area is around the 2 moving averages. We need to establish support on 21 EMA. We have to also see how we react with the 50 SMA. If we get ABOVE 50 SMA and maintain support, it is likely we print a GOLDEN CROSS, leading to BUY pressure to come in.
This could be the necessary catalyst for trend change.
Another hint in an attempt to trend change is the 21 EMA flattening out, beginning to show signs of a curvature to upside.
Now lets Look left to find evidence of previous patterns in the Moving average interactions, Support line interaction and MACD.
Our first time interacting with the SUpport line, we had many touches, before printing a GOLDEN CROSS. ALong with MACD CROSS ABOVE 0 level, we had a 48% Uptrend.
Our 2nd interaction with SUpport line, we experienced a fakeout on the 1st touch. MACD could NOT move ABOVE 0 level.
The 2nd touch of support line, had the GOLDEN CROSS and the MACD cross ABOVE 0 level. This lead to an extended Bull run for CVS with gains of 100%.
Keep this in mind. Look for similar pattern in our current price action. If we see a Golden Cross with MACD crossing ABOVE 0 level. This would mean an UPTREND is probable. But dont discount the possibility of a fakeout. We can always have another attempt to test support on support line.
Watch closely for these to develop in our current price action. Best opportunity to invest would be after Golden cross has been established with confirmed MACD cross Above 0 level in my opinion.
__________________________________________________________________________________
Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again.
Stay tuned for more updates on CVS in the near future.
If you have any questions, do reach out. Thank you again.
DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. Do not use my ideas for the basis of your trading strategy, make sure to work out your own strategy and when trading always spend majority of your time on risk management strategy.
Potential Up Trend on Gland Pharma Ltd (NSE), Fib RetracementThis is my personal view that Gland Pharma Ltd ha very potential uptrend for coming future.
I tried to figure it out with the Fib Retracement with Anchored volume profile.
As I have noticed it retraced exactly from -1.618 (905.85).
Target 1.618, which is 3190.45
Let me know if you have different views..
Thanks for viewing.
UNH on watch for continuation after pullback LONGUNH after earnings with a mild beat in mid July, price shot up for one week then went
sideways and then pulled back in the past week. Price is now at 497 and under
the dynamic resistance of the first deviation line above the mean VWAP. The dual
time frame shows a good pattern with the shorter TF of 3 minutes in green above the
longer TF of 45 minutes in black. The short TF is above the 50 level.
Overall, I think the pullback is about over. I will take a long trade with a buy stop of
500.25 setting the stop loss below what will become dynamic support of the blue
line at 499.5. This is a tight stop and low risk owing to the positioning of the trade
about a support level. I will target 515.00 for a risk to reward ratio of 0.75 to 15
or 1:20 which is outstanding. I may take a call option striking $510 out a couple of months
if it would not draw down by the cash portion of my overall portfolio more than 3%. This
option premium is about $9000 but I think the potential profit is about the same.
OSCR Earnings Beat Setup LONGOSCR on the daily chart is shown near to but below the POC line on the volume
profile anchored in April. The ZL MACD has a low amplitude histogram. On
the directional index indicator both negative and positive lines are nearly trendless
at the 20 level. The price is closer to the lower Bollinger Bands and so a reversion
to the mean would be upward price action.
I am looking to take a long trade here. The entry would be by a buy stop over
the POC line at 7.35 and the stop loss at 7.05, the low of the last red candle.
The targets are 8.75 and 9.85 corresponding to horizontal resistance lines.
This is a swing trade planning for a profit of about 30%. The stop loss of 0.30
as compared with an average target of 1.75 is about 1:5 for the risk to reward.
I may take an options trade of 1-3 months duration as well. Leave a commnet , if
you would like to know my considerations for a call option. Healthcare and medical
are relatively strong sectors right now compared with the chaotic market at large.
CVAC - Trade Opportunity Looking through charts, CVAC caught my eye for some potential trade opportunities.
Firstly lets look at the candle close of Today 08/01/23
-> We are currently testing this RED Resistance Arrow Line pointing down
-> The candle has a lower wick, indicating some buying pressure
->However, the candle body is small, which may indicate waning momentum
**If price action CONFIRMS above RED ARROW -> This can be a TRADE SETUP
-> If this plays out - TARGET = $10.65 or a potential 17% move
-> STOP LOSS should be placed below RED ARROW
Notice the GREEN circle indicating a bounce UP from 2 converging support lines
-> The 200 DMA -> this is important as if we maintain support on 200 DMA, it indicates Bullish activity, price has a possibility of traveling back to UPPER BLACK RESISTANCE LINE
BUT NOTE: This is the first time for CVAC to be doing this, so we have to be cautious, as FAKEOUTS are possible.
-> The orange sloping support line
~~ Having 2 support lines converge makes SUPPORT two-folds stronger, which may create ncessary momentum for price to break above RED ARROW
Now Notice how the ORANGE SUPPORT LINE coincides with the ORANGE line found on the RSI and MACD
-> This is known as a BEARISH DIVEGENCE -> Where price shows a higher low but Indicators show lower lowers.
-> This leads to PRICE DECLINES if it plays out, may lead Price Action to go towards the BLACK Support line or where the RED ARROW is pointing at.
-> Its also not necessary that it plays out right away, we can technically hit my TARGET of $10.65 and then have the DIVERGENCE play out.
*** Regardless of what happens, BLACK SLOPING SUPPORT LINE can be a BUY ZONE with STOP LOSS BELOW this line. This would be to catch a bounce off this line.
RSI orange line MUST stay above or act as SUPPORT on the BLACK moving average, this normally leads to PRICE increasing
MACD (Momentum indicator)
-> must continue this histogram pattern of waning bearish momentum, we must print GREEN histogram.
-> There needs to be a BULLISH CROSS where BLUE line crosses above the ORANGE line.
-> This would help us breakout of the RED ARROW RESISTANCE
STOCH RSI
-> BLUE line has CROSSED over ORANGE, and we are ABOVE the 20 level. This indicates BULLISH MOMENTUM.
-> We must continue UPWARD above the 80 level, this indicates continuation of MOMENTUM, if we keep this direction -> It may HELP us BREAKOUT of RED ARROW RESISTANCE LINE.
CONCLUSION:
All in all, we are in a interesting area for CVAC the stock. New things are happening in the price action, that has not been seen in the history of CVAC. 200 DMA acting as support for the 1st time, STOCH RSI Bullish cross and waning of bearish momentum in MACD can be the necessary catalyst to push PRICE above the RED ARROW RESISTANCE. If so TARGET = $10.65 or a 17% Trade. However, it is important to note the BEARISH DIVERGENCE forming, though a sign of DOWNWARD PRICE ACTION, can also lead to opportunity of a trade setup. Never fight the trend, its always better to ride along.
Thanks you! Hope this helps, please support my ideas by boosting, following and commenting! Do check out my page of other trade ideas. I have linked a couple of recent ideas ive had, check em out if you'd like.
DISCLAIMER: This is not Financial advice, i am NOT a Financial advisor. Thoughts expressed here are my only my opinion and for educational purposes. Do practice due diligence and focus on risk mamangement. Deploy stop losses to protect yourself. Thanks.
TDOC - Update after a Bullish WeekIve been eyeing TDOC for some time, finally posting a chart on it talking about TA developments that may indicate a potential bottom area earlier this week (Check below for the link to that chart). I was also in the camp of TDOC going lower to the low $20 or high Teens ($18-19).
This weeks move of 30%, closing the weekly candle at 20% gains was a wonderful surprise.
Its important to NOTE, however that the move is NOT SET IN STONE yet -> For WEEKLY Timeframe
We are hitting a MAJOR confluence of RESISTANCES. Though we are ever so peaking our head out atm, next 1-2 weeks will show more evidence with confirmation.
FOr example: Next week CLOSE being a bullish single candle or next couple weeks printing a bullish candlestick pattern sequence.
The other side is that It could very well be a fake out/ SELL OFF and we do come back down to make a final lower low before we really become bullish. But in my opinion, the probability of a fake out maybe less.
We've moved above the 21 week EMA as well, we would need to confirm support above it in the coming weeks but being above 21 EMA indicates bullish activity.
NOTICE the Bollinger bands. Notice how it has narrowed, this could indicate volitility to pick up and we need to see price stay above median line and be near the upper band. We must Observe what happens in the coming weeks.
The Bollinger median line and 21 EMA are converging and can act as strong support zone. If we do come back down in price.
On the DAILY timeframe, we acted as SUPPORT on both the PURPLE major RESISTANCE line from all time highs and RESISTANCE line from July 2022. Just note however i would need more confirmation in the coming days by staying above as support, to be confident we stay at these levels. If we do, next weeks candle stays above and no fakeout occurs.
RSI is breaking out of the Horizontal resistance line that kept RSI range bound since OCT 2021. (indicated by black line)
This tells me, the BULLISH DIVERGENCE is at play. We would want RSI to continue UP, or follow the Green arrowed path drawn. We absolutely do NOT want the Red arrow. Which is a possibility but less probable in my opinion.
STOCH RSI, a momentum indicator shows that we have a bullish momentum cross, showing that there is still gas left in the tank for us to move. Expect it to go above the 80 level.
Conclusion + trade setups:
For stocks that are 80+% off there tops, averaging in always is a nice strategy.
I think under $30 is cheap for TDOC, especially with all these TA challenges being slowly conquered. There is no denying that it is highly probable we go up eventually, as we've reached critical historical support, and have been consolidating around here for awhile. Alot of indicators and other signs are leaning towards a bottom being formed or already formed.
*CHECK OUT A more detailed TDOC chart from earlier this week BELOW*
A swing trade idea could be taking positions using the Daily timeframe, putting stop loss below the PURPLE line. Making sure you manage your risk properly.
I would rely more on the WEEKLY timeframe and a confirmation that we've made it above the resistance, plus weekly candles are more macro and powerful. This would also be for holding/ longer term investing.
THANK YOU! Hope this update helped. If you like the content, please boost and follow. Please do comment with your opinions! Would love a discussion.
DISCLAIMER: I am not a Financial advisor. This is NOT financial advise. This is my opinion and for educational purposes.
TDOC - Teladoc bottom fishingHello. This chart is strictly a Technical Analysis of Teladoc (TDOC).
I think currently we are in a point in TDOC's price action where we've reached a fundamental SUPPORT area if you look back to 2016. This could potentially be opportune BUY ZONE.
TA is all about probability. The probability we go down is always there, just in this scenario i believe the probability of downside is less compared to the upside.
Though i want some short term downside for TDOC, as i believe that would be the necessary catalyst to help shift trend to upside. Price will eventually rally up, especially if we are in a bull market currently. Which i believe we are in. Ill go into details on why i want it and believe this.
NOTE: This is on the WEEKLY timeframe, so we are looking into a more macro scenario than if we were to look at DAILY timeframe.
LAST WEEk -> We printed a candle that has a large upper wick, indicating SELLING pressure.
We are also resting right on top of a major support level at around $23, indicated by green horizontal like.
It wouldnt be bad for price to drop below and touch the lower 2 green lines, the sloping one and horizontal one. This would be a catalyst due to price action then, starting to confirm what is known as a BULLISH DIVERGENCE.
Which is a pattern or concept where PRICE ACTION forms LOWER LOWS, as INDICATORS create HIGHER LOWERS -> Seen by the white sloping line drawn in the RSI and MACD. And the green sloping line in PRICE ACTION indicates the lower lows.
*Many trades ive recently taken have followed similar patterns, ill link 1 chart to compare this to BELOW* Its for stock LMND. Heres also a SNAP SHOT.
NOTICE the horizontal white line on RSI -> this is what helps me guage at when this move and UPSIDE can start or hit. If RSI breaks out above this line, we can start to see BULLISH DIVERGENCE playout. Easily i can see TDOC hitting around the $40.00 level.
Going back to CURRENT price action. I believe we go down and test the lower green lines, because of all this RESISTANCE that we are facing.
NOTICE:
#PURPLE SLOPING RESISTANCE LINE -> This is MAJOR MAJOR resistance, created since Feb 2021. We just tested it for the 3rd time, last week. (Note: atleast 3 touches are required to weaken lines, more price touches lines -> the weaker they get.)
# We also got some short term WHITE SLOPING RESISTANCE LINES. Helping to push price down
# We also got the 21 EMA (YELLOW Moving average)
******Note, all these are meeting together to act as RESISTANCE. When theres so many converging, like this -> It gets a little hard or takes time to break through to upside.
***ALso i think the PURPLE line is MOST IMPORTANT. This would help reverse trend in a major macro way.
SO KEEP OBSERVING.
Lastly, note the ADX & DI -> This is a momentum indicator. When RED line is over Green line, it indicates BEARISH Price action, as you can see by the downtrend. Currently there is some green overlapping occuring. We have to keep observing to see how this progresses. But ideally, we'd like to see Green shoot up to above 20 level, just like the red line did in white box.
CONCLUSION: I believe in the short term, we could have some downside price action coming. But sometimes, downside action could have positive ramifications. In this case, further strengthening the BULLISH DIVERGENCE forming in the charts. Indicators and current support area, indicate seller exhausting. Probabilities in my opinion point to price moving up than down. Hitting either one of the lower green support lines, could be areas where positions can be taken with stop losses set below.
DISCLAIMER: This is by NO MEANS, Financial advice. I am not a financial advisor, im just a TA nerd and post these for educational purpose. Always follow your own due diligence when trading/investing. Always focus most of your energy on risk management strategies.
If you like this content, please do BOOST, FOLLOW and do COMMENT, i would like others opinions on what your seeing, whether TA or FA. Thank you.